UrologyNews.net

Urology Xagena

Search results for "Anti-PDL1"

Results from a phase I open-label study that showed the investigational cancer immunotherapy MPDL3280A ( anti-PDL1 ) shrank tumours ( overall response rate ) in 43% ( 13/30 ) of people previously trea ...